Enteric microorganism combination and application thereof as systemic lupus erythematosus marker

The invention discloses an enteric microorganism combination and an application thereof as a systemic lupus erythematosus marker. Particularly, 16s rRNA sequencing is carried out on enteric microorganism samples from systemic lupus erythematosus individuals and healthy individuals to determine Sporo...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Hauptverfasser:	LU XUE, ZHONG JINHE, LU PINLING, LI SHUIXIAN, LIN ZHIMING, HUANG JINGMEI, YANG LIU, XIE BAOZHAO, LAI CHUNTAO
Format:	Patent
Sprache:	chi ; eng
Schlagworte:	BEER BIOCHEMISTRY CHEMISTRY COMPOSITIONS OR TEST PAPERS THEREFOR COMPOSITIONS THEREOF CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL ORENZYMOLOGICAL PROCESSES CULTURE MEDIA ENZYMOLOGY HUMAN NECESSITIES HYGIENE INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIRCHEMICAL OR PHYSICAL PROPERTIES MEASURING MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEICACIDS OR MICROORGANISMS MEDICAL OR VETERINARY SCIENCE METALLURGY MICROBIOLOGY MICROORGANISMS OR ENZYMES MUTATION OR GENETIC ENGINEERING PHYSICS PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES PROCESSES OF PREPARING SUCH COMPOSITIONS PROCESSES USING MICROORGANISMS PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS SPIRITS TESTING VINEGAR WINE
Online-Zugang:	Volltext bestellen
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	The invention discloses an enteric microorganism combination and an application thereof as a systemic lupus erythematosus marker. Particularly, 16s rRNA sequencing is carried out on enteric microorganism samples from systemic lupus erythematosus individuals and healthy individuals to determine Sporobacter, Butyricimonas and Phascolarctobacterium which have level difference in SLE patients, and the relationship between the level difference and the SLE is defined. The enteric microorganisms with the level difference can be used as markers of the SLE. 本发明公开了肠道微生物组合及其作为系统性红斑狼疮标志物的应用，具体的本发明通过分别对来自系统性红斑狼疮个体和健康个体的肠微生物样品进行16s rRNA测序，确定SLE患者中存在的水平差异的孢子杆菌(Sporobacter)、丁酸弧菌(Butyricimonas)、和考拉杆菌(Phascolarctobacterium)，并明确了这些水平差异与系统性红斑狼疮的关系。这些具有水平差异的肠道微生物能够作为系统性红斑狼疮的标志物。